Literature DB >> 8414415

The time course of irradiation changes in proton beam-treated uveal melanomas.

E S Gragoudas1, K M Egan, M A Saornil, S M Walsh, D M Albert, J M Seddon.   

Abstract

BACKGROUND: Although histopathologic changes in uveal melanomas treated by irradiation have been well characterized, the timing of these effects after irradiation has not been previously evaluated.
METHODS: The series consisted of a total of 92 eyes with uveal melanoma, enucleated at various intervals after proton irradiation (range, 1 month to 8 years) due to complications (n = 66) or tumor growth (n = 22), or at autopsy (n = 4). Study slides were read, using a standard protocol, by two pathologists masked to the timing of the enucleation after irradiation and the reason for the surgery.
RESULTS: The prevalence of inflammation decreased whereas fibrosis increased with time from 15% of cases enucleated within 12 months (early cases) to 61% of those enucleated more than 30 months (late cases) after irradiation (P for trend = 0.0005). Tumor necrosis and blood vessel damage occurred early, and the prevalence of these changes was constant over time. Excluding tumors with evidence of growth after irradiation, mitotic figures became progressively less common as the interval between irradiation and enucleation increased (P for trend = 0.015); no mitotic figures were present in 40 high-power fields more than 30 months after irradiation.
CONCLUSION: Histopathologic changes in irradiated melanomas vary according to the time elapsed since irradiation. Inflammation decreases with time whereas fibrosis becomes more prevalent with time after irradiation. Among controlled tumors, mitotic figures appear only in recently irradiated tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414415     DOI: 10.1016/s0161-6420(93)31445-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

3.  [Histological findings in an irradiated choroidal melanoma].

Authors:  S Koinzer; H Hasselbach; J H Bräsen; I Leuschner; J Roider
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

Review 4.  Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications.

Authors:  Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Rocco Luca Emanuele Liardo; Roberto Milazzotto; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2021-06-04

5.  Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea.

Authors:  Tae Wan Kim; Euncheol Choi; Jeonghoon Park; Dong-Ho Shin; Su Kyung Jung; Susie Seok; Kwan Ho Cho; Joo-Young Kim; Dae Yong Kim; Tae Hyun Kim; Yang Kwon Suh; Yeon Joo Kim; Sung Ho Moon
Journal:  Cancer Res Treat       Date:  2017-04-19       Impact factor: 4.679

6.  Regression patterns of choroidal melanoma: After palladium-103 (103Pd) plaque brachytherapy.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Eur J Ophthalmol       Date:  2018-05-22       Impact factor: 2.597

7.  Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.

Authors:  Samuel K Houston; Nisha V Shah; Christina Decatur; Marcela Lonngi; William Feuer; Arnold M Markoe; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2013-01-22

8.  Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy.

Authors:  Marina Marinkovic; Lennart J Pors; Vincent van den Berg; Femke P Peters; Ann Schalenbourg; Leonidas Zografos; Alessia Pica; Jan Hrbacek; Sjoerd G Van Duinen; T H Khanh Vu; Jaco C Bleeker; Coen R N Rasch; Martine J Jager; Gregorius P M Luyten; Nanda Horeweg
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.